Literature DB >> 18008330

Interleukin-4 stimulates androgen-independent growth in LNCaP human prostate cancer cells.

Soo Ok Lee1, Elaine Pinder, Jae Yeon Chun, Wei Lou, Meng Sun, Allen C Gao.   

Abstract

BACKGROUND: Clinical data showed that the levels of interleukin-4 (IL-4) are significantly elevated in serum of patients with ablation resistant prostate cancer. Previous studies demonstrated that IL-4 enhances androgen receptor (AR) activation mediated by NF-kappaB in the absence or in the very low levels of androgen in prostate cancer cells. In this study, the role of IL-4 in promoting the growth of androgen-independent prostate cancer cells was examined.
METHODS: LNCaP cells were transfected with a full-length IL-4 cDNA and stable clones expressing IL-4 were selected. The growth of LNCaP cells expressing IL-4 was analyzed in vitro and in vivo both in the presence and absence of androgen.
RESULTS: Overexpression of IL-4 enhances the growth of androgen-sensitive LNCaP cells in culture media containing charcoal-stripped FBS condition (CS-FBC), and increases the sensitivity of LNCaP cells in response to androgen stimulation. The DHT-mediated cell growth could not be blocked by bicalutamide in IL-4 overexpressing LNCaP cells, but can be neutralized by bicalutamide in parental LNCaP and neo control cells. Furthermore, overexpression of IL-4 stimulates tumor growth of androgen-sensitive LNCaP cells both in intact and castrated male mice.
CONCLUSIONS: Overexpression of IL-4 increases the sensitivity of androgen-sensitive LNCaP prostate cancer cells in response to androgen stimulation and enhances the growth of LNCaP cells both in the presence and absence of androgen in vitro and in vivo. These studies suggest that IL-4 plays an important role in promoting androgen-independent prostate cancer growth. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18008330     DOI: 10.1002/pros.20691

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  22 in total

Review 1.  Mechanisms of persistent activation of the androgen receptor in CRPC: recent advances and future perspectives.

Authors:  Nagalakshmi Nadiminty; Allen C Gao
Journal:  World J Urol       Date:  2011-10-19       Impact factor: 4.226

2.  The CXCL12/CXCR4 axis promotes ligand-independent activation of the androgen receptor.

Authors:  Sathish Kasina; Jill A Macoska
Journal:  Mol Cell Endocrinol       Date:  2012-01-08       Impact factor: 4.102

3.  NDRG2 acts as a negative regulator downstream of androgen receptor and inhibits the growth of androgen-dependent and castration-resistant prostate cancer.

Authors:  Chuigong Yu; Guojun Wu; Ruixiao Li; Lei Gao; Fan Yang; Yi Zhao; Jian Zhang; Rui Zhang; Jing Zhang; Libo Yao; Jianlin Yuan; Xia Li
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

4.  Upregulation of androgen-responsive genes and transforming growth factor-β1 cascade genes in a rat model of non-bacterial prostatic inflammation.

Authors:  Yasuhito Funahashi; Katherine J O'Malley; Naoki Kawamorita; Pradeep Tyagi; Donald B DeFranco; Ryosuke Takahashi; Momokazu Gotoh; Zhou Wang; Naoki Yoshimura
Journal:  Prostate       Date:  2013-12-17       Impact factor: 4.104

5.  Genetic polymorphisms in inflammation pathway genes and prostate cancer risk.

Authors:  Erika M Kwon; Claudia A Salinas; Suzanne Kolb; Rong Fu; Ziding Feng; Janet L Stanford; Elaine A Ostrander
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-03-23       Impact factor: 4.254

6.  Interleukin-4 activates androgen receptor through CBP/p300.

Authors:  Soo Ok Lee; Jae Yeon Chun; Nagalakshmi Nadiminty; Wei Lou; Siting Feng; Allen C Gao
Journal:  Prostate       Date:  2009-02-01       Impact factor: 4.104

7.  Chemokine markers predict biochemical recurrence of prostate cancer following prostatectomy.

Authors:  David L Blum; Tatsuki Koyama; Amosy E M'Koma; Juan M Iturregui; Magaly Martinez-Ferrer; Consolate Uwamariya; Joseph A Smith; Peter E Clark; Neil A Bhowmick
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

8.  Suppressor of cytokine signaling (SOCS)-1 is expressed in human prostate cancer and exerts growth-inhibitory function through down-regulation of cyclins and cyclin-dependent kinases.

Authors:  Hannes Neuwirt; Martin Puhr; Frédéric R Santer; Martin Susani; Wolfgang Doppler; Gemma Marcias; Veronika Rauch; Maria Brugger; Alfred Hobisch; Lukas Kenner; Zoran Culig
Journal:  Am J Pathol       Date:  2009-03-26       Impact factor: 4.307

9.  The expression of androgen-responsive genes is up-regulated in the epithelia of benign prostatic hyperplasia.

Authors:  Katherine J O'Malley; Rajiv Dhir; Joel B Nelson; James Bost; Yan Lin; Zhou Wang
Journal:  Prostate       Date:  2009-12-01       Impact factor: 4.104

10.  IL4 limits the efficacy of tumor-targeted antibody therapy in a murine model.

Authors:  Rishi Surana; Shangzi Wang; Wei Xu; Sandra A Jablonski; Louis M Weiner
Journal:  Cancer Immunol Res       Date:  2014-09-09       Impact factor: 11.151

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.